Side effects put a hold on Isis Phase III studies

Isis Pharmaceuticals Inc. on Friday announced that it has temporarily halted Phase III studies of ISIS 2922 in AIDS patients with cytomegalovirus (CMV) retinitis after observing side effects in some treated patients. The company said the trial schedule would be delayed two to six months, and it will use a lower dose of the antisense drug when it resumes the studies.

Wall Street reaction was mild. ISIP lost $0.875, closing at $8.25 on 663,600 shares traded.